Phuturdex › Diseases › Obstructive sleep apnea
Drugs in development · updated 30 October 2026
Obstructive sleep apnea: drugs in development
As of 30 October 2026 there are 37 active clinical trials (recruiting or ongoing, phases I–III) on 32 drugs for obstructive sleep apnea. 20 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Ecnoglutide InjectionXW003 injection | III | 2 | NCT07387094 |
| GZR18 | III | 2 | NCT07501832 |
| HDM1005 | III | 2 | NCT07794397 |
| Maridebart cafraglutide | III | 2 | NCT07225686 |
| NNC0487-0111 | III | 2 | NCT07571109 |
| UBT251 | III | 2 | NCT07806851 |
| Aroxybutynin | III | 1 | NCT06566820 |
| Berobenatide | III | 1 | NCT07881757 |
| EloralintideLY3841136 | III | 1 | NCT07369011 |
| HRS9531 | III | 1 | NCT06974851 |
| HRS9531placebo | III | 1 | NCT06974851 |
| DAW2020 | I–II | 1 | NCT04538755 |
| IHL-42X | II | 1 | NCT07635563 |
| LTM1201AD | I–II | 1 | NCT03858751 |
| LTM1201AG | I–II | 1 | NCT03858751 |
| LTM1201AT | I–II | 1 | NCT03858751 |
| LTM1201AZ | I–II | 1 | NCT03858751 |
| Reboxetine | II | 1 | NCT05978505 |
| SASS-001 | II | 1 | NCT06776432 |
| Sivopixant | II | 1 | NCT06776432 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| AtomoxetineAtoncy®, Strattera® | III | 4 | NCT06566820 |
| EszopicloneLunesta®, Lunivia® | III | 4 | NCT07332442 |
| DronabinolTetrahydrocannabinol, Delta-9-THC | II–III | 2 | NCT07570953 |
| TirzepatideZepbound, Mounjaro | II–III | 1 | NCT07846865 |
| AcetazolamideDiamox® | I–II | 5 | NCT05293600 |
| LemborexantDayvigo® | I–II | 2 | NCT07683442 |
| TrazodoneRaldesy®, Oleptro® | I–II | 2 | NCT05293600 |
| ApripitantAprepitant, Aponvie® | II | 1 | NCT06462287 |
| OxybutyninGelnique 3%®, Oxytrol For Women® | II | 1 | NCT05933603 |
| Oxygen gas | II | 1 | NCT05237505 |
| Oxytocin nasal sprayOxytocin 10 Usp Units In Dextrose 5%®, Oxytocin 5 Usp Units In Dextrose 5%® | I | 1 | NCT03860233 |
| MorphineArymo Er®, Morphabond Er® | Early I | 1 | NCT06854211 |
Sorted by most advanced phase and number of active trials.
All 32 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Broader categories
- Respiratory disease 57 drugs
- Nervous System Diseases 39 drugs
- Respiration disorder 6 drugs
- Sleep-wake disorder 11 drugs
- Apnea 4 drugs
- Sleep apnea 10 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D020181 “Sleep Apnea, Obstructive”.